{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T11:04:35Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 23.5, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09548-f3c2-7923-a4cc-c2eb4bbd9dd4\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: lumiracoxib\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: 1001 reg", "usd": 0.0, "recall": true }, "codex": { "seconds": 94.7, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09548-f3ce-7c22-a8e7-8e69c521864c\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: lumiracoxib\nRegistry id: vr.tr.lumiracoxib\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\n" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:49:52+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:30+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q413744", "registryId": "vr.tr.lumiracoxib", "name": "lumiracoxib", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q413744/", "model": { "registry_id": "vr.tr.lumiracoxib", "name": "lumiracoxib", "purpose": "Enable an agent to identify lumiracoxib, assess the quality and condition of a material containing it, and determine which handling or research uses have adequate evidence and authorization.", "definition": "Lumiracoxib is a synthetic phenylacetic acid derivative and selective cyclooxygenase-2 (COX-2) inhibitor developed as a nonsteroidal anti-inflammatory drug for relief of pain and inflammation.", "scope_statement": "This model owns lumiracoxib as the chemical substance registered as vr.tr.lumiracoxib in PHY / PHY.MAT, including molecular identity, material forms, analytical quality, pharmacological properties, hazards and jurisdiction-specific use constraints.", "in_scope": [ "Molecular identity and identifiers distinguishing lumiracoxib from related NSAIDs", "Free-acid identity and relationships to salts, solid forms and solutions", "Batch purity, impurities, degradation and analytical confirmation", "Condition-dependent physical properties and storage suitability", "COX inhibition evidence, hepatic safety evidence and their limits", "Dated regulatory restrictions and material-handling requirements" ], "out_of_scope": [ "Finished medicinal products, their excipients, packaging and commercial identity", "Patient diagnosis, prescribing, dosing and individualized treatment decisions", "Manufacturing processes and synthesis-route operating instructions", "Metabolites and related NSAIDs as independent chemical substances", "Clinical trials, adverse-event cases and regulatory proceedings as standalone entities" ], "distinguishing_features": [ "Match molecular connectivity to 2-[2-[(2-chloro-6-fluorophenyl)amino]-5-methylphenyl]acetic acid; matching a drug-class label alone is insufficient.", "Check the parent formula C15H13ClFNO2 and PubChem CID 151166 against structural evidence. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Lumiracoxib)", "Distinguish it from diclofenac through the fluorine-containing substitution pattern and additional methyl group on the phenylacetic-acid ring.", "Distinguish it from celecoxib by its carboxylic-acid structure rather than a sulfonamide-bearing structure.", "Distinguish a lumiracoxib material from a branded medicine or metabolite by confirming the actual chemical species and other constituents." ], "characteristics": [ { "name": "Chemical identity", "kind": "category", "unit_or_values": "Parent molecular structure; formula C15H13ClFNO2; PubChem CID 151166", "why_it_matters": "Anchors identity to a specific compound rather than to a product name or pharmacological class. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Lumiracoxib)" }, { "name": "Registry identifier correspondence", "kind": "relation", "unit_or_values": "vr.tr.lumiracoxib; CAS 220991-20-8; other identifiers require verification", "why_it_matters": "Supports record matching while requiring confirmation that each identifier denotes the same chemical form. [EU substance listing](https://eur-lex.europa.eu/legal-content/SL-EN/TXT/?from=SL&uri=CELEX%3A32007R0129)" }, { "name": "Material form", "kind": "category", "unit_or_values": "Free acid, explicitly identified salt, characterized solid form, solution or unresolved form", "why_it_matters": "Determines whether mass, concentration and physical-property comparisons refer to equivalent material." }, { "name": "Assay and impurity profile", "kind": "measurement", "unit_or_values": "Mass fraction or chromatographic area percentage with method and reporting basis; impurity concentrations in specified units", "why_it_matters": "Distinguishes parent-compound content from method-dependent purity estimates and identifies suitability limits." }, { "name": "Ionization and solubility", "kind": "measurement", "unit_or_values": "pKa; solubility in mg/mL or mol/L with pH, solvent, temperature and material form", "why_it_matters": "Supports preparation of interpretable lumiracoxib solutions without assuming nominal concentration equals dissolved concentration." }, { "name": "Thermal and solid-state behavior", "kind": "measurement", "unit_or_values": "Melting or decomposition temperature in °C; pressure, method and solid-form identification", "why_it_matters": "Helps evaluate material identity and processing limits without confusing decomposition with boiling." }, { "name": "COX inhibition", "kind": "measurement", "unit_or_values": "COX-1 and COX-2 IC50 or other explicitly identified endpoints in nM or µM, with assay conditions", "why_it_matters": "Makes selectivity claims comparable only where biological systems and measurement methods permit comparison." }, { "name": "Hepatic safety evidence", "kind": "relation", "unit_or_values": "Linked studies or assessments with exposure context, outcome and uncertainty", "why_it_matters": "Serious liver effects motivated EMA's 2007 recommendation to withdraw lumiracoxib-containing medicines. [EMA assessment](https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-withdrawal-marketing-authorisations-lumiracoxib-containing-medicines)" }, { "name": "Storage condition and integrity", "kind": "state", "unit_or_values": "Documented storage history; intact, degraded, expired, quarantined or unassessed", "why_it_matters": "Connects the present material state to evidence supporting continued analytical or experimental use." }, { "name": "Applicable restrictions", "kind": "relation", "unit_or_values": "Jurisdiction, authority, decision date, permitted activity, product or substance scope, and verification date", "why_it_matters": "Prevents historical medicinal-product decisions from being treated as universal rules for every lumiracoxib material or activity." } ], "affordances": [ "Resolve a supplier or registry record to lumiracoxib using structural and identifier evidence.", "Assess whether a batch is suitable for a specified analytical or nonclinical experiment.", "Compare solubility, stability and COX inhibition results under compatible conditions.", "Flag material for reanalysis or quarantine when identity, degradation or purity evidence is inadequate.", "Determine which jurisdiction-specific checks are needed before procurement, transfer or use.", "Trace safety and handling decisions to dated evidence while preserving unresolved questions." ], "agent_conduct": { "may": [ "Describe lumiracoxib's class as a selective COX-2 inhibitor and its regulatory history.", "Explain that it was withdrawn in many countries because of serious liver injury." ], "must_not": [ "Recommend, supply or dose it for a person.", "Help obtain it from unregulated sources where it has been withdrawn.", "Downplay the liver toxicity that led to its withdrawal." ], "requires_human": [ "Any decision about pain or arthritis treatment for a person." ] }, "ethics": { "considerations": [ "Its history shows the duty to act on post-marketing safety signals." ], "affected_parties": [ "Patients with arthritis or pain", "Prescribers" ] }, "owners": { "steward": "The marketing authorisation holder where it remains licensed; medicines regulators decide its status.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Identity cannot be settled by sight; tablets must be confirmed by label and pharmacy records." ], "failure_modes_and_hazards": [ "Serious liver injury, including cases requiring transplantation.", "Gastrointestinal and cardiovascular risks shared with the drug class." ], "what_it_is_for": [ "Lumiracoxib is encountered in pharmaceutical research and reference materials as a selective COX-2 inhibitor developed to relieve pain and inflammation.", "Its association with serious liver injury makes authorization history and material provenance relevant when assessing proposed uses." ], "standards_and_regulation": [ "The Anatomical Therapeutic Chemical classification maintained by the WHO Collaborating Centre for Drug Statistics Methodology assigns lumiracoxib code M01AH06 within the coxibs." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q413744: lumiracoxib", "url": "https://www.wikidata.org/wiki/Q413744", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Lumiracoxib", "url": "https://en.wikipedia.org/wiki/Lumiracoxib", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "lumiracoxib-identity", "name": "Lumiracoxib identity", "description": "Establish the exact parent compound and distinguish it from related chemicals and product names.", "rationale": "Shared NSAID terminology and commercial synonyms cannot establish chemical equivalence.", "layers": [ { "id": "parent-structure", "name": "Parent structure", "description": "Recognize lumiracoxib through connectivity and substitution pattern.", "findings": [ { "id": "structural-identity-test", "name": "Structural identity test", "description": "Require agreement between the proposed lumiracoxib identity and a structure-specific reference.", "questions": [ { "text": "Does the structure contain the 2-chloro-6-fluorophenylamino group and the 5-methylphenylacetic-acid framework?", "kind": "definition", "id": "structural-identity-test-q01" }, { "text": "Which reference structure and analytical observations establish that the sample is lumiracoxib rather than a related NSAID?", "kind": "provenance", "id": "structural-identity-test-q02" } ] } ] }, { "id": "names-and-chemical-boundaries", "name": "Names and chemical boundaries", "description": "Resolve identifiers while keeping products, derivatives and metabolites distinct.", "findings": [ { "id": "identifier-and-form-resolution", "name": "Identifier and form resolution", "description": "Attach identifiers to their documented chemical species and treat product names as contextual links.", "questions": [ { "text": "Which authoritative records connect the supplied name and CAS number to the parent lumiracoxib structure?", "kind": "provenance", "id": "identifier-and-form-resolution-q01" }, { "text": "Does the record describe parent lumiracoxib, a salt, a metabolite, a mixture or a finished medicine?", "kind": "boundary", "id": "identifier-and-form-resolution-q02" } ] } ] } ] }, { "id": "lumiracoxib-material-quality", "name": "Lumiracoxib material quality", "description": "Represent chemical form, parent-compound content and batch-specific contaminants.", "rationale": "A lumiracoxib label does not establish the composition or fitness of a supplied material.", "layers": [ { "id": "form-and-content", "name": "Form and content", "description": "Separate chemical species, solid form and assay reporting basis.", "findings": [ { "id": "parent-equivalent-content", "name": "Parent-equivalent content", "description": "Require the material form and assay basis before interpreting weighed lumiracoxib quantities.", "questions": [ { "text": "Is the material the free acid, a characterized salt or a form whose identity remains unresolved?", "kind": "definition", "id": "parent-equivalent-content-q01" }, { "text": "What is the measured lumiracoxib content, and is it reported as received, on a dry basis or as parent equivalents?", "kind": "measurement", "id": "parent-equivalent-content-q02" } ] } ] }, { "id": "impurities-and-authentication", "name": "Impurities and authentication", "description": "Assess evidence that distinguishes lumiracoxib from impurities and degradation products.", "findings": [ { "id": "batch-analytical-confidence", "name": "Batch analytical confidence", "description": "Link identity and purity conclusions to methods, reference materials and batch records.", "questions": [ { "text": "Which chromatographic and spectroscopic results authenticate this lumiracoxib batch?", "kind": "provenance", "id": "batch-analytical-confidence-q01" }, { "text": "Which related substances, residual solvents, water content and unidentified peaks were measured, and with what limits?", "kind": "measurement", "id": "batch-analytical-confidence-q02" }, { "text": "Does the analytical evidence satisfy the requirements of the proposed experiment or require reanalysis?", "kind": "action", "id": "batch-analytical-confidence-q03" } ] } ] } ] }, { "id": "lumiracoxib-physical-state", "name": "Lumiracoxib physical state", "description": "Represent condition-dependent dissolution, solid-state behavior and stability.", "rationale": "Lumiracoxib's acid functionality and material form make preparation and storage conditions relevant to usable concentration.", "layers": [ { "id": "ionization-and-dissolution", "name": "Ionization and dissolution", "description": "Assess the conditions under which lumiracoxib is dissolved and chemically interpretable.", "findings": [ { "id": "verified-solution-state", "name": "Verified solution state", "description": "Distinguish weighed loading from measured dissolved parent compound.", "questions": [ { "text": "What measured pKa and solubility evidence applies to the specified lumiracoxib form, solvent, pH and temperature?", "kind": "measurement", "id": "verified-solution-state-q01" }, { "text": "Does dilution into the intended assay medium cause precipitation or a change in dissolved concentration?", "kind": "measurement", "id": "verified-solution-state-q02" } ] } ] }, { "id": "thermal-and-storage-stability", "name": "Thermal and storage stability", "description": "Connect lumiracoxib condition to thermal characterization and storage history.", "findings": [ { "id": "condition-supported-usability", "name": "Condition-supported usability", "description": "Require form-specific evidence for thermal properties, storage limits and solution lifetime.", "questions": [ { "text": "Which measured transitions correspond to melting, solvent loss or decomposition, and which lumiracoxib solid form was tested?", "kind": "measurement", "id": "condition-supported-usability-q01" }, { "text": "What evidence supports storage temperature, light protection and usable lifetime for this solid or solution?", "kind": "provenance", "id": "condition-supported-usability-q02" }, { "text": "Do excursions, freeze-thaw history or observed changes require an integrity check before use?", "kind": "action", "id": "condition-supported-usability-q03" } ] } ] } ] }, { "id": "lumiracoxib-biological-evidence", "name": "Lumiracoxib biological evidence", "description": "Represent COX inhibition and exposure-related evidence without converting it into prescribing instructions.", "rationale": "Lumiracoxib is classified as a COX-2 inhibitor, but potency, selectivity and exposure require contextual evidence. [EMA](https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-withdrawal-marketing-authorisations-lumiracoxib-containing-medicines)", "layers": [ { "id": "cox-assay-context", "name": "COX assay context", "description": "Make inhibition and selectivity claims conditional on the experimental system.", "findings": [ { "id": "comparable-cox-inhibition", "name": "Comparable COX inhibition", "description": "Record target, species, preparation, endpoint and exposure conditions for each potency result.", "questions": [ { "text": "What COX-1 and COX-2 inhibition values were measured for lumiracoxib, using which assay systems and endpoints?", "kind": "measurement", "id": "comparable-cox-inhibition-q01" }, { "text": "Were the measurements sufficiently matched to support the reported selectivity ratio and its direction?", "kind": "boundary", "id": "comparable-cox-inhibition-q02" } ] } ] }, { "id": "exposure-and-metabolite-boundaries", "name": "Exposure and metabolite boundaries", "description": "Separate parent-compound exposure from administered amount and metabolite observations.", "findings": [ { "id": "parent-exposure-interpretation", "name": "Parent exposure interpretation", "description": "Link pharmacokinetic and metabolism observations to their biological context and measured chemical species.", "questions": [ { "text": "Which species, matrix, route and sampling conditions support the reported lumiracoxib exposure or clearance?", "kind": "provenance", "id": "parent-exposure-interpretation-q01" }, { "text": "Does the analytical result quantify parent lumiracoxib, unbound parent, a named metabolite or combined drug-related material?", "kind": "boundary", "id": "parent-exposure-interpretation-q02" } ] } ] } ] }, { "id": "lumiracoxib-safety-and-permissions", "name": "Lumiracoxib safety and permissions", "description": "Connect hepatic safety evidence, material hazards and dated restrictions to proposed activities.", "rationale": "The history of serious liver injury makes an evidence-backed distinction between pharmacological activity, material handling and authorized use essential.", "layers": [ { "id": "hepatic-safety-evidence", "name": "Hepatic safety evidence", "description": "Preserve the serious liver-risk signal and the limits of risk prediction.", "findings": [ { "id": "liver-risk-and-uncertainty", "name": "Liver risk and uncertainty", "description": "EMA recommended withdrawal of lumiracoxib-containing medicines in December 2007 following its assessment of serious liver effects. [EMA recommendation](https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-withdrawal-marketing-authorisations-lumiracoxib-containing-medicines)", "questions": [ { "text": "Which primary studies and regulatory assessments establish the liver-injury outcomes and exposure contexts?", "kind": "provenance", "id": "liver-risk-and-uncertainty-q01" }, { "text": "Which proposed metabolic mechanisms or susceptibility markers are supported, and which remain hypotheses?", "kind": "boundary", "id": "liver-risk-and-uncertainty-q02" } ] } ] }, { "id": "laboratory-material-hazards", "name": "Laboratory material hazards", "description": "Determine handling requirements for the actual lumiracoxib preparation.", "findings": [ { "id": "preparation-specific-handling", "name": "Preparation-specific handling", "description": "Use applicable hazard documentation for solid lumiracoxib or its particular solution rather than translating clinical risk directly into a GHS classification.", "questions": [ { "text": "Which current safety data sheet supplies the applicable GHS classification and handling requirements for this preparation?", "kind": "provenance", "id": "preparation-specific-handling-q01" }, { "text": "Are lumiracoxib-specific exposure limits established, and what documented controls apply where limits are unavailable?", "kind": "action", "id": "preparation-specific-handling-q02" }, { "text": "Which solvent hazards and waste requirements additionally apply to a lumiracoxib solution?", "kind": "action", "id": "preparation-specific-handling-q03" } ] } ] }, { "id": "jurisdiction-and-use-status", "name": "Jurisdiction and use status", "description": "Resolve permission for a defined activity using current, geographically applicable evidence.", "findings": [ { "id": "dated-activity-authorization", "name": "Dated activity authorization", "description": "Keep historical withdrawal recommendations distinct from verified current decisions and their product or activity scope.", "questions": [ { "text": "Which authority and dated record establish the current status of the relevant lumiracoxib product or activity in this jurisdiction?", "kind": "provenance", "id": "dated-activity-authorization-q01" }, { "text": "Does that record govern medicinal marketing, research procurement, import, possession or another specifically defined activity?", "kind": "boundary", "id": "dated-activity-authorization-q02" }, { "text": "What documented conditions must be satisfied before the proposed procurement, transfer or use proceeds?", "kind": "action", "id": "dated-activity-authorization-q03" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This account is recalled knowledge; no sources were consulted.", "Current authorisation and availability require jurisdiction-specific verification; historical marketing does not establish present availability.", "Purity specifications, solid forms, melting point and formal hazard classifications should be checked against authoritative substance records." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of lumiracoxib this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "lumiracoxib", "note": "Generic name for the active substance." }, { "scheme": "CAS Registry Number", "value_or_pattern": "220991-20-8", "note": "Identifies lumiracoxib as a chemical substance." }, { "scheme": "WHO Anatomical Therapeutic Chemical (ATC) classification", "value_or_pattern": "M01AH06", "note": "Classified among the coxibs." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of lumiracoxib this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Historically marketed for symptomatic relief of osteoarthritis.", "Studied for relief of acute pain.", "Used in research comparing the efficacy and safety of selective COX-2 inhibitors with other NSAIDs." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of lumiracoxib this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass", "typical_range": "293.72", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of lumiracoxib this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Serious liver injury, including liver failure, prompted regulatory withdrawals.", "Cardiovascular thrombotic events are a concern associated with selective COX-2 inhibition.", "Gastrointestinal ulceration and bleeding remain possible despite COX-2 selectivity.", "Renal impairment, fluid retention and hypertension can occur." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of lumiracoxib this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Australia withdrew lumiracoxib in 2007 following reports of serious liver injury.", "European regulatory action in 2007 led to withdrawal of marketing authorisations over liver safety concerns." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of lumiracoxib this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "celecoxib", "difference": "Both selectively inhibit COX-2, but celecoxib has a different chemical scaffold and is a distinct active substance." }, { "name": "diclofenac", "difference": "Both are related to phenylacetic acid chemistry, but lumiracoxib is classified as a selective COX-2 inhibitor and has a different molecular structure." }, { "name": "Prexige", "difference": "Prexige is a brand associated with lumiracoxib medicines; lumiracoxib is the active chemical substance rather than the formulated product." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of lumiracoxib this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which authoritative records confirm lumiracoxib's EC number, if assigned, and distinguish identifiers for the parent acid from any separately registered forms?", "Which primary measurements establish pKa, condition-specific solubility, solid forms and thermal behavior, including whether a meaningful boiling point is available before decomposition?", "Which impurity specifications, validated analytical methods and stability data support the intended lumiracoxib material grade?", "What current jurisdiction-specific medicinal and research statuses, GHS classifications and occupational exposure limits can be verified?", "How well do primary studies establish lumiracoxib's hepatic injury mechanisms and susceptibility factors, and what uncertainty remains in predicting risk?" ], "statistics": { "bundles": 6, "layers": 12, "findings": 18, "questions": 33 } }